BioSpace News Archive

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the closing of its previously announced underwritten public offering of 17,275,000 shares of its common stock, which includes the underwriters’ full exercise of their option to purchase additional shares and pre-funded

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock.

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory

Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States

ACell, Inc., a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects, announced today that it has launched the roadshow for the initial

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020 , its common stock has been approved for uplisting to the Nasdaq Global Select Market ® and will continue trading under its

BioSerenity, a high growth company specializing in remote diagnostic solutions for Neurology, Sleep Medicine and Cardiology announces an article published in Epilepsy & Behavior describing deployment of innovative virtual clinics to provide improved access to care for people suffering from epilepsy. Healthcare access rem

Italian clinical study finds combined strains of live bacteria reduced diarrhea and lessened progression of symptoms in hospitalized COVID-19 patients

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the European Heart Journal highlighting the benefits of Stereotaxis’ robotic technology in a COVID-19 patient. The publication concludes that catheter ablation “should be performed preferably with a remote navigation system in order to minimize the infectious risk of the staff of the electrop

ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors Company expects topline data in the second half of 2021 WESTLAKE VILLAGE, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that it initiated enrollment in the Phase